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Aim: Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second
or third line nab-paclitaxel ± durvalumab. Patients & methods: Longitudinal QoL was assessed using Lung
Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and
Treatment of Cancer Quality of Life Questionnaire 30-item core. Results: QoL was generally stable through
eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung
Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab])
and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item
core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + dur-
valumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely
resolved at least once in 19–56% and 9–51% of patients, respectively. Conclusion: While QoL trends were
promising, additional data are required to support these regimens in this setting.
First draft submitted: 3 December 2019; Accepted for publication: 6 March 2020; Published online:
31 March 2020
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Patients with advanced non-small cell lung cancer (NSCLC) have a high symptom burden that adversely af-
fects their quality of life (QoL), which predictably worsens with the greater symptom burden associated with
advanced disease [1,2]. In addition, QoL has been shown to significantly worsen with disease progression in patients
with advanced NSCLC [3,4]. Therefore, QoL maintenance during second-line therapy for NSCLC is a valuable
consideration for treatment decisions.
nab-Paclitaxel is currently approved in combination with carboplatin for frontline treatment of advanced
NSCLC [5]. In the first-line setting, nab-paclitaxel + carboplatin has demonstrated clinically meaningful im-
provement in QoL from baseline [6]. Immune checkpoint inhibitors (ICIs) can improve outcomes with chemother-
Future Oncol. (2020) 16(12), 749–762 ISSN 1479-6694 74910.2217/fon-2019-0796 C© 2020 Celgene
Research Article Ponce Aix, Talbot, Govindan et al.
apy [7–12], including nab-paclitaxel [10–12], in first-line treatment of advanced NSCLC. Nivolumab, pembrolizumab
and atezolizumab are currently approved for second-line treatment of NSCLC [13]. Additionally, durvalumab as
monotherapy has been shown to improve patient outcomes [14] and according to National Comprehensive Cancer
Network guidelines, is a category 1 recommendation as consolidation treatment for patients with unresectable
stage III disease that responded to platinum-based chemoradiation [15]. Additionally, targeted therapies have shown
favorable QoL profiles [16–18]. However, to our knowledge, few studies have evaluated QoL, especially longitudinal
QoL, in patients receiving second or third-line treatment.
The Phase II ABOUND.2L+ trial (NCT02250326) investigated treatment with second or third line nab-
paclitaxel either alone or in combination with CC-486 (oral azacitidine) or durvalumab in patients with advanced
NSCLC. The primary outcome of ABOUND.2L+ demonstrated no benefit of combining CC-486 with nab-
paclitaxel; the median progression-free survival (PFS) was 3.2 months with nab-paclitaxel + CC-486 versus
4.2 months with nab-paclitaxel alone (hazard ratio: 1.3; 95% CI: 0.9–1.9) [19]. In the third arm of the study, the
combination of nab-paclitaxel with durvalumab demonstrated a median PFS of 4.5 months [20]. The objective of
this analysis was to evaluate QoL data collected from the nab-paclitaxel alone and nab-paclitaxel + durvalumab
arms, which demonstrated promising efficacy outcomes [19,20]. QoL outcomes with nab-paclitaxel + CC-486 were
not reported because the regimen was found to be ineffective in this setting.
Patients & methods
Study design
The study was approved by the institutional review board or independent ethics committee at participating sites
and conducted in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki. All
patients provided written informed consent prior to treatment initiation.
Inclusion and exclusion criteria as well as sample size determination for the randomized part of this open-label
study were described previously [19]. Briefly, patients with advanced nonsquamous NSCLC, one prior platinum-
based chemotherapy and no activating EGFR mutations or ALK translocations were randomized 1:1 to receive
nab-paclitaxel 100 mg/m2 on days 8 and 15 + CC-486 200 mg on days 1–14 or nab-paclitaxel 100 mg/m2 on days
1 and 8 of each 21-day cycle. Randomization, when conducted, was performed centrally using a permuted-block
randomization method. After enrollment for the nab-paclitaxel alone and nab-paclitaxel + CC-486 arms was
completed, the ABOUND.2L+ protocol was amended to include a third arm, in which patients with advanced
nonsquamous or squamous NSCLC and one prior platinum-based chemotherapy were enrolled. Patients were
assigned to this third arm and received nab-paclitaxel 100 mg/m2 on days 1 and 8 + durvalumab 1125 mg
on day 15 of a 21-day cycle. Hence, randomization did not occur between the nab-paclitaxel + durvalumab and
nab-paclitaxel alone arms. The primary end point was PFS. Key secondary end points were overall survival, response
rates and safety. QoL was an exploratory end point.
QoL assessments
QoL questionnaires were completed by patients on day 1 of each cycle. Assessments were conducted using the Lung
Cancer Symptom Scale (LCSS), EuroQoL Five-Dimensions Five-Levels (EQ-5D-5L) and European Organisation
for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (EORTC QLQ-C30), which
have been previously validated [21–23].
The LCSS has nine components: appetite, fatigue, cough, dyspnea, hemoptysis, pain, lung cancer symptoms,
normal activity and global QoL. Each item is measured on a 100-mm visual analog scale (VAS). The LCSS
composite scores include total score (average of all component scores), symptom burden index (average of appetite,
fatigue, cough, dyspnea, hemoptysis and pain scores), pulmonary symptom scale (average of cough, dyspnea and
hemoptysis scores), overall constitutional score (average of appetite and fatigue scores) and three-item index (sum
of lung cancer symptoms, normal activity and global QoL scores; this index is measured on a 300-mm VAS). The
LCSS total scores (0–100) were transformed by subtracting from 100 such that in the final outcome, a higher LCSS
total score represents better health status and QoL.
The EQ-5D-5L measures five dimensions: mobility, self-care, usual activities, pain/discomfort and
anxiety/depression. Readouts include utility and VAS scores (a higher score represents better health status).
The EORTC QLQ-C30 is a 30-item assessment with readouts including global health status/QoL, physical
functioning, role functioning, emotional functioning, cognitive functioning, social functioning, fatigue, nausea
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Table 1. Baseline patient characteristics for patients who received nab-paclitaxel alone.
Characteristic nab-P (n = 80)
Age (years)
Median (range) 63.0 (37–82)
≥ 65 years 39 (48.8)
≥ 70 years 19 (23.8)






Black or African American 2 (2.5)
Asian 2 (2.5)
Other 1 (1.3)








Data are n (%) unless otherwise noted.
ECOG PS: Eastern Cooperative Oncology Group performance status; nab-P: nab-paclitaxel; nab-P + D: nab-paclitaxel + durvalumab.
and vomiting and pain. For global health status/QoL and functioning scales, a higher score represents better health
status. For symptom scales, a lower score represents better health status.
For items measured on a VAS, improvement ≥10 mm was considered clinically meaningful [24]. For the LCSS
three-item index, improvement ≥30 mm was considered clinically meaningful [25].
Patients with QoL data at baseline and ≥1 postbaseline assessment were included. Data cutoffs were 30 August
2017 for the nab-paclitaxel alone arm and 23 December 2017 for the nab-paclitaxel + durvalumab arm.
Results
Baseline patient characteristics
The ABOUND.2L+ trial included 80 patients randomized to the nab-paclitaxel alone arm and 79 patients assigned
to the nab-paclitaxel + durvalumab arm. The baseline demographics by treatment arm are reported in Table 1 and
2. Notable differences were that the nab-paclitaxel + durvalumab arm included patients with both squamous and
nonsquamous histology (the nab-paclitaxel alone arm included only patients with nonsquamous NSCLC) and had
a higher frequency of patients with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 1
(77.2 vs 67.5% for nab-paclitaxel + durvalumab vs nab-paclitaxel alone).
QoL assessment completion
A total of 55 (68.8%) and 69 (87.3%) patients completed a baseline QoL assessment in the nab-paclitaxel alone
and nab-paclitaxel + durvalumab arms, respectively. However, a total of 50 (62.5%) and 58 (73.4%) patients,
respectively, completed a baseline and ≥1 postbaseline QoL assessment.
LCSS results
The LCSS total score (represented as mean change from baseline) was stable through eight cycles of treatment
in both arms, with no clinically meaningful changes during the first eight cycles (Figure 1A & B). The mean
maximum change from baseline showed stable QoL in all five LCSS composite scores in the nab-paclitaxel alone
arm (Figure 2A), and in three of the five composite scores (total score, symptom burden index and pulmonary
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Table 2. Baseline patient characteristics for patients who received nab-paclitaxel + durvalumab.
Characteristic nab-P + D (n = 79)
Age (years)
Median (range) 63.0 (29–84)
≥ 65 years 36 (45.6)
≥ 70 years 25 (31.6)






Black or African American 1 (1.3)
Asian 0
Other 0







Not specified 1 (1.3)
Data are n (%) unless otherwise noted.
ECOG PS: Eastern Cooperative Oncology Group performance status; nab-P: nab-paclitaxel; nab-P + D: nab-paclitaxel + durvalumab.
symptoms) in the nab-paclitaxel + durvalumab arm (Figure 2B). In addition, clinically meaningful improvement
was noted in the three-item index and overall constitutional score in the nab-paclitaxel + durvalumab arm.
LCSS component and composite scores were stable through the first eight cycles of treatment in both arms
(Table 3 & 4), with a few exceptions observed primarily in the nab-paclitaxel alone arm. Among patients who
received nab-paclitaxel alone, clinically meaningful improvement occurred in the cough item in several cycles,
and in dyspnea, global QoL and pulmonary symptoms at cycle 7; clinically meaningful deterioration occurred in
fatigue, hemoptysis, lung cancer symptoms, normal activity and overall constitutional score at cycle 8 (Table 3).
Interestingly, the mean maximum scores showed clinically meaningful improvement in seven of the nine items in
the nab-paclitaxel alone arm, and in eight of the nine items in the nab-paclitaxel + durvalumab arm; the scores for
hemoptysis in both arms and lung cancer symptoms in the nab-paclitaxel alone arm were stable.
EQ-5D-5L results
EQ-5D-5L VAS score (represented as mean change from baseline) was stable through eight cycles of treatment in
both arms (Figure 3A & B), with the exception of a clinically meaningful deterioration noted in the nab-paclitaxel
alone arm at cycle 8. The domains of mobility, self-care, usual activities, pain/discomfort and anxiety/depression
were stable or improved from baseline in 29–56% (Figure 4A) and 19–48% (Figure 4B) of patients in the nab-
paclitaxel alone and nab-paclitaxel + durvalumab arms, respectively. The domains were completely resolved at least
once during treatment in 9–39% (Figure 4C) and 31–51% (Figure 4D) of patients in the nab-paclitaxel alone and
nab-paclitaxel + durvalumab arms, respectively.
EORTC QLQ-C30 results
EORTC QLQ-C30 scores were generally stable through the first eight cycles of treatment in both arms, with the
exception of clinically meaningful deterioration in role functioning at cycles 6 and 8 with nab-paclitaxel alone
(Table 5) and at cycle 8 with nab-paclitaxel + durvalumab (Table 6), and improvement in emotional and cognitive
functioning beginning with cycles 4 and 5, respectively, as well as social functioning at cycle 7 in the nab-paclitaxel
alone arm. Mean maximum EORTC QLQ-C30 scores showed clinically meaningful improvement in emotional
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Table 3. Mean change from baseline over time and mean maximum improvement from baseline in patients treated with




















Appetite -2.3 2.0 6.9 2.5 0.7 8.8 -9.8 -1.7 11.5
Fatigue -3.7 -1.8 3.2 1.1 -8.6 7.8 -13.2 -13.2 10.9
Cough 1.9 8.1 15.0 11.0 6.2 20.8 5.1 10.2 16.8
Dyspnea -1.6 2.6 7.9 6.8 3.6 13.2 -7.0 6.9 11.8
Hemoptysis 2.6 1.9 0.4 -3.8 -6.1 -1.8 -15.4 -7.4 5.5
Pain -1.3 -4.5 4.9 5.2 -1.7 8.4 -6.9 -6.0 11.5
Lung cancer
symptoms
-0.1 3.5 -0.3 3.3 -7.4 5.5 -14.3 -3.7 9.7
Normal
activity
1.0 -5.2 1.1 -4.7 -7.5 4.5 -12.2 -17.0 12.1




1.0 4.2 7.8 4.7 1.2 10.7 -5.8 3.2 9.6
Three-item
index‡
0.6 4.5 6.4 6.0 -9.7 24.8 -21.1 -24.4 25.0
Symptom
burden index§




-3.0 0.1 5.1 1.8 -3.9 8.3 -11.5 -7.5 9.5
A higher score represents a better health status.
†Average of cough, dyspnea and hemoptysis scores.
‡Sum of lung cancer symptoms, normal activity and global QoL scores. This index is measured on a 300-mm scale, with clinically meaningful improvement defined as ≥30 mm.
§Average of appetite, fatigue, cough, dyspnea, hemoptysis and pain scores.
¶Average of appetite and fatigue scores.
C: Cycle; D: Day; LCSS: Lung Cancer Symptom Scale; nab-P: nab-paclitaxel; nab-P + D: nab-paclitaxel + durvalumab; QoL: Quality of life.
Table 4. Mean change from baseline over time and mean maximum improvement from baseline in patients treated




















Appetite 1.4 -1.0 2.9 6.3 5.2 -3.5 2.8 4.7 16.0
Fatigue -3.0 -2.0 1.8 7.6 -1.8 0.1 0.1 -4.2 15.2
Cough -5.1 -3.1 4.2 5.0 6.2 2.9 3.0 6.7 14.7
Dyspnea -4.1 -1.3 -1.3 2.8 0.7 -4.3 2.0 -2.2 11.5
Hemoptysis 2.2 0.6 2.8 4.0 1.5 0.8 4.7 -0.3 5.5
Pain 5.3 2.4 -1.6 5.6 8.0 7.3 2.4 9.0 15.1
Lung cancer symptoms 2.9 2.0 0.1 5.3 12.5 7.6 6.1 5.9 16.4
Normal activity -4.5 -1.7 1.3 2.7 0.8 -4.1 -4.8 -2.2 11.3
Global QoL -1.5 -4.7 -1.3 0.4 -3.5 -6.1 -9.2 -5.2 10.9
LCSS composite
Pulmonary symptoms† -2.3 -1.3 1.9 3.9 2.8 -0.2 3.2 1.4 9.2
Three-item index‡ -3.1 -4.4 0.1 8.5 9.7 -2.7 -7.9 -1.6 30.4
Symptom burden index§ -0.5 -0.7 1.5 5.2 3.3 0.5 2.5 2.3 9.3
Overall constitutional score¶ -0.8 -1.5 2.3 7.0 1.7 -1.7 1.5 0.3 13.0
A higher score represents a better health status.
†Average of cough, dyspnea and hemoptysis scores.
‡Sum of lung cancer symptoms, normal activity and global QoL scores. This index is measured on a 300-mm scale, with clinically meaningful improvement defined as ≥30 mm.
§Average of appetite, fatigue, cough, dyspnea, hemoptysis and pain scores.
¶Average of appetite and fatigue scores.
C: Cycle; D: Day; LCSS: Lung Cancer Symptom Scale; nab-P: nab-paclitaxel; nab-P + D: nab-paclitaxel + durvalumab; QoL: Quality of life.
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42 33 29 23 19 12 1012nab-P
Cycle, day
C2D1 C3D1Baseline C4D1 C5D1 C6D1 C7D1 C9D1C8D1
Improvement
nab-P
C2D1 C3D1Baseline C4D1 C5D1 C6D1 C7D1 C9D1C8D1
Improvement
nab-P + D
Figure 1. Change from baseline in quality of life (Lung Cancer Symptom Scale total score†). (A) Patients who
received nab-P alone and (B) Patients who received nab-P + D. A higher score represents a better health status.
†Average of appetite, fatigue, cough, dyspnea, hemoptysis, pain, lung cancer symptoms, normal activity and global
QoL scores.
C: Cycle; D: Day; nab-P: nab-paclitaxel; nab-P + D: nab-paclitaxel + durvalumab; QoL: Quality of life.
functioning and global health status/QoL in both arms (Figure 5A & B), and in pain (decreased score denotes
improvement) in the nab-paclitaxel + durvalumab arm. Physical, role, cognitive and social functioning, as well as
fatigue and nausea/vomiting were stable in both arms.
Performance status deterioration
Among those who received nab-paclitaxel alone and had a baseline ECOG PS 0, 18 (78.3%) patients experienced
a performance status deterioration of ≥1; among those who had a baseline ECOG PS 1, 15 (26.3%) patients
experienced a performance status deterioration of ≥1. Among those who received nab-paclitaxel + durvalumab
and had a baseline ECOG PS 0, 15 (83.3%) patients experienced a performance status deterioration of ≥1; among
those who had a baseline ECOG PS 1, 22 (36.1%) patients experienced a performance status deterioration of ≥1.
Discussion
The results of this analysis show that in general, QoL scores were stable or improved through the first eight cycles of
treatment with two nab-paclitaxel-based regimens used in the ABOUND.2L+ study: nab-paclitaxel alone and nab-
paclitaxel + durvalumab. Clinically meaningful improvement in mean maximum improvement occurred in both
treatment arms in the LCSS components of fatigue, cough, dyspnea, appetite, pain, normal activity and global QoL.
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Improvement nab-P+D
#
Figure 2. Improvement from baseline in Lung Cancer Symptom Scale composite scores (mean maximum). (A)
Patients who received nab-P alone and (B) Patients who received nab-P + D. A higher score represents a better health
status.
†Average of appetite, fatigue, cough, dyspnea, hemoptysis, pain, lung cancer symptoms, normal activity and global
QoL scores.
‡Average of appetite, fatigue, cough, dyspnea, hemoptysis and pain scores.
§Average of cough, dyspnea and hemoptysis scores.
¶Sum of lung cancer symptoms, normal activity and global QoL scores. This item is measured on a 300-mm scale, with
clinically meaningful improvement defined as ≥30 mm.
#Average of appetite and fatigue scores.
nab-P: nab-paclitaxel; nab-P + D: nab-paclitaxel + durvalumab; QoL: Quality of life.
Clinically meaningful improvement was also noted in lung cancer symptoms in the nab-paclitaxel + durvalumab
arm. In the EQ-5D-5L domains, 19–56% of patients reported stable or improved status, while 9–51% of patients
reported complete resolution of a problem in a domain at least once. Clinically meaningful improvement in mean
maximum improvement also occurred in EORTC QLQ-C30 emotional functioning and global health status/QoL
(nab-paclitaxel alone and nab-paclitaxel + durvalumab) and pain (nab-paclitaxel + durvalumab) scores. The
impact of nab-paclitaxel-based regimens on QoL observed in our study is supported by a previous report of nab-
paclitaxel + carboplatin for frontline treatment of patients with squamous NSCLC, which reported stable QoL
through four cycles of induction treatment based on LCSS scores, and stable or improved status in the EQ-5D-5L
domains in ≥83% of patients [6].
Given the high symptom burden in patients with advanced NSCLC [2] as well as the significantly worse QoL
associated with disease progression [3,4], it is important to consider the impact of treatment on specific symptoms as
well as overall QoL and other clinical outcomes. The nab-paclitaxel-based regimens employed in this trial generally
kept symptom severity, as assessed by LCSS component scores, stable throughout treatment, with little clinically
meaningful deterioration.
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Figure 3. Change from baseline in quality of life (EuroQoL Five-Dimensions Five-Levels Visual Analog Scale score†).
(A) Patients who received nab-P alone and (B) Patients who received nab-P + D. A higher score represents a better
health status.
†EQ-5D-5L VAS score records the patient’s self-rated health on a VAS with end points ‘The best health you can
imagine’ and ‘The worst health you can imagine’. VAS score was calculated using the US Crosswalk Index Value set.
C: Cycle; D: Day; EQ-5D-5L: EuroQoL Five-Dimensions Five-Levels; nab-P: nab-paclitaxel; nab-P + D: nab-paclitaxel +
durvalumab; QoL: Quality of life; VAS: Visual analog scale.
Beyond the physical impact of NSCLC, the assessments reported here also examined the psychological and
social impacts of the disease. Previous studies revealed the presence of psychological and social problems facing
patients with NSCLC, including anxiety, lung cancer-related stigma and depression and have suggested an as-
sociation between anxiety and depression with mortality in these patients [26–28]. In the current study, based on
EORTC QLQ-C30, emotional functioning showed clinically meaningful improvement compared with baseline
at several time points throughout the treatment in the nab-paclitaxel alone arm and remained stable in the nab-
paclitaxel + durvalumab arm. Additionally, the anxiety/depression domain of the EQ-5D-5L was completely
resolved at least once in 37 and 50% of patients in the nab-paclitaxel alone and nab-paclitaxel + durvalumab
arms, respectively. Although our findings cannot be compared directly with those from previous studies, a possible
explanation could be the promising activity with treatment, but such interpretations must be made cautiously due
to potential survivor selection bias in longitudinal QoL analyses.
The current National Comprehensive Cancer Network guidelines for NSCLC include ICIs (nivolumab, pem-
brolizumab and atezolizumab) as category 1, preferred subsequent therapy options for patients without prior ICI
therapy [15]. In addition, docetaxel, pemetrexed (nonsquamous), gemcitabine, or ramucirumab plus docetaxel are
category 2A options. Given the major impact of ICIs plus chemotherapy in the first-line setting, there will con-
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Figure 4. Resolution of problems† (EuroQoL Five-Dimensions Five-Levels). Stable or improved from baseline (nab-P
alone [A] or nab-P + D [B]) or complete resolution of symptoms at least once (nab-P alone [C] or nab-P + D [D]). The
percentage of patients with a stable or improved dimension is based on the population with a baseline assessment.
The percentage of patients with a dimension completely resolved at least once is based on the population with a
problem in the given dimension at baseline. (A) Stable or improved from baseline (nab-P alone). (B) Stable or
improved from baseline (nab-P + D). (C) Complete resolution of symptoms at least once (nab-P alone). (D) Complete
resolution of symptoms at least once (nab-P + D).
†Patients rate their health state in each domain as ‘no problems’, ‘slight problems’, ‘moderate problems’, ‘severe
problem’ and ‘extreme problems’. A dimension is stable or improved if it stays the same or improves compared with
baseline during the study. A dimension is completely resolved if the score becomes ‘no problems’.
nab-P: nab-paclitaxel; nab-P + D: nab-paclitaxel + durvalumab.
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49 49 49 49 49 49 49 49 49
nab-P
Figure 5. Improvement from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire
30-item core scores (mean maximum). (A) Patients who received nab-P alone and (B) Patients who received nab-P + D. For global health
status/QoL and functioning scales, a higher score represents a better health status. For symptom scales, a lower score represents a better
health status.
†Includes items 29 and 30 on the EORTC QLQ-C30. † ‡ § ¶ #
‡Includes items 1–5.
§Includes items 6 and 7.
¶Includes items 21–24.
#Includes items 20 and 25.
††Includes items 26 and 27.
‡‡Includes items 10, 12 and 18.
§§Includes items 14 and 15.
¶¶Includes items 9 and 19.
EORTC QLQ-C30: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core; nab-P:
nab-paclitaxel; nab-P + D: nab-paclitaxel + durvalumab; QoL: Quality of life.
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Table 5. Mean change from baseline over time in patients treated with nab-paclitaxel alone (European Organisation for

















Global health status/QoL† 0.60 7.07 1.72 1.81 0.00 0.00 -1.39 -6.67
Physical functioning‡ -4.44 -3.03 -5.98 -3.48 -6.32 -0.56 -8.89 -16.67
Role functioning§ -2.38 -7.58 -7.47 -5.80 -10.53 -4.17 -13.89 -21.67
Emotional functioning¶ 5.56 7.32 10.34 14.86 18.42 17.36 10.42 6.67
Cognitive functioning# 3.57 7.58 6.90 11.59 10.53 11.11 11.11 13.33
Social functioning†† 1.59 3.54 -5.17 2.90 -1.75 13.89 5.56 5.00
Fatigue‡‡ 3.44 5.05 6.13 1.45 -1.17 -3.70 2.78 5.56
Nausea and vomiting§§ 0.79 1.01 2.87 0.72 3.51 1.39 6.94 8.33
Pain¶¶ -0.40 0.00 2.30 -7.97 -0.88 2.78 9.72 15.00
For global health status/QoL and functioning scales, a higher score represents a better health status. For symptom scales, a lower score represents a better health status.
† Includes items 29 and 30 on the EORTC QLQ-C30.
‡ Includes items 1–5.
§ Includes items 6 and 7.
¶ Includes items 21–24.
#Includes items 20 and 25.
†† Includes items 26 and 27.
‡‡ Includes items 10, 12 and 18.
§§ Includes items 14 and 15.
¶¶ Includes items 9 and 19.
C: Cycle; D: Day; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core; nab-P: nab-paclitaxel; nab-P + D: nab-
paclitaxel + durvalumab; QoL: Quality of life.
Table 6. Mean change from baseline over time in patients treated with nab-paclitaxel + durvalumab (European

















Global health status/QoL† 2.08 4.59 1.55 4.07 0.45 -1.19 -1.88 0.00
Physical functioning‡ -0.90 -2.04 0.16 -0.16 -4.50 -5.14 -9.03 -9.28
Role functioning§ -5.13 -2.38 -1.55 -4.65 -4.50 -7.14 -11.83 -15.22
Emotional functioning¶ 2.72 1.53 5.43 5.62 4.73 5.24 8.06 0.36
Cognitive functioning# 1.60 -0.34 0.78 2.71 0.00 3.81 -0.54 -2.17
Social functioning†† -4.49 -5.78 -1.55 -2.71 -1.80 -4.76 -5.38 -2.17
Fatigue‡‡ 1.28 0.45 0.26 -1.03 5.11 5.71 9.32 12.56
Nausea and vomiting§§ -0.64 0.68 -2.33 -2.71 -4.05 -1.90 0.00 -5.07
Pain¶¶ -2.56 -0.68 0.39 -3.49 -5.41 -2.86 1.61 1.45
For global health status/QoL and functioning scales, a higher score represents a better health status. For symptom scales, a lower score represents a better health status.
† Includes items 29 and 30 on the EORTC QLQ-C30.
‡ Includes items 1–5.
§ Includes items 6 and 7.
¶ Includes items 21–24.
#Includes items 20 and 25.
†† Includes items 26 and 27.
‡‡ Includes items 10, 12 and 18.
§§ Includes items 14 and 15.
¶¶ Includes items 9 and 19.
C: Cycle; D: Day; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core; nab-P: nab-paclitaxel; nab-P + D: nab-
paclitaxel + durvalumab; QoL: Quality of life.
tinue to be a need for subsequent treatment options. Therefore, the promising activity [19] and QoL results of the
ABOUND.2L+ trial suggest nab-paclitaxel monotherapy could be considered following disease progression.
There are some limitations to our study. First, 63–73% of patients completed baseline and ≥1 postbaseline
QoL assessment, which may affect the interpretation of the results. As is the case in any longitudinal QoL study,
patients who continue to receive treatment and whose QoL is measured tend to be those with better outcomes,
and this potential survivor selection bias needs to be considered. Second, patients were not randomized to the nab-
paclitaxel + durvalumab arm, as was done for the other arms of the ABOUND.2L+ study, and certain differences
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between the arms reported here exist. Most notably, the nab-paclitaxel + durvalumab arm included patients
with both squamous and nonsquamous histology, while the nab-paclitaxel alone arm only included nonsquamous
histology.
Conclusion
At present, neither nab-paclitaxel monotherapy nor nab-paclitaxel + durvalumab are standards of care as subsequent
therapy for NSCLC. When the ABOUND.2L+ trial was designed, pemetrexed and docetaxel were considered
standards of care for subsequent therapy in NSCLC. However, an increased trend in first-line pemetrexed and
potential concerns with second-line docetaxel fueled the need for more subsequent therapy options. Although
nab-paclitaxel monotherapy or in combination with durvalumab are not standards of care for subsequent therapy,
the primary publication of the ABOUND.2L+ trial reported encouraging outcomes with nab-paclitaxel alone [19],
and the present findings suggest promising QoL trends. However, additional data are required to further support
the potential use of these regimens as treatment options in this setting. Furthermore, these results may encourage
future trials of additional nab-paclitaxel-based regimens in advanced NSCLC.
Summary points
• Quality of life (QoL) is an important consideration during treatment in patients with advanced non-small cell lung
cancer (NSCLC).
• The aim of this analysis was to evaluate QoL in patients with advanced NSCLC who received nab-paclitaxel alone
or nab-paclitaxel + durvalumab in the second or third line setting in the ABOUND.2L+ trial.
• A total of 80 and 79 patients were enrolled to receive nab-paclitaxel alone or nab-paclitaxel + durvalumab,
respectively; 50 (62.5%) and 58 (73.4%) patients, respectively, completed a baseline and ≥1 postbaseline QoL
assessment.
• Lung Cancer Symptom Scale (LCSS) total score was stable through eight treatment cycles in both arms. LCSS
component and composite scores were largely stable or improved. Clinically meaningful improvement was noted
in the three-item index and overall constitutional score in the nab-paclitaxel + durvalumab arm. Mean maximum
component scores showed clinically meaningful improvement in both the nab-paclitaxel alone (seven of nine
items) and nab-paclitaxel + durvalumab (eight of nine items) arms.
• EuroQoL Five-Dimensions Five-Levels scores were stable through eight treatment cycles in both arms, except for
clinically meaningful deterioration in the nab-paclitaxel alone arm beginning with cycle 8. All domains were
stable or improved in 19–56% of patients and completely resolved at least once in 9–51% of patients.
• European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core scores
were stable or improved through eight treatment cycles, except for clinically meaningful deterioration in role
functioning at later cycles. Mean maximum scores showed clinically meaningful improvement in emotional
functioning and global health status/QoL in both arms, and in pain reduction in the nab-paclitaxel + durvalumab
arm.
• QoL was generally stable or improved through eight cycles of nab-paclitaxel alone or
nab-paclitaxel + durvalumab as second or third line treatment in patients with NSCLC.
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